Abstract
Background A 45-year-old man presented with frontal headache and visual disturbances to our clinic. For the previous 5 years, he had been receiving treatment for long-lasting mild hyperthyroidism with antithyroid therapy, but therapy had not been carefully followed. During the last 2 years he had also complained of erectile dysfunction and loss of libido. On physical examination, he had a small goiter, normal skin, no Graves' ophthalmopathy, normal BMI, and reduced testis volume and pubic hair.
Investigations Serum levels of free T3 and T4, serum prolactin, testosterone, serum gonadotropins, insulin-like growth factor 1, adrenocorticotropic hormone, and cortisol were measured. MRI scan, TSH-releasing hormone test, and T3 suppression test were carried out. Levels of pituitary glycoprotein hormone α-subunit and sex-hormone-binding protein were also measured.
Diagnosis Hyperthyroidism caused by a mixed pituitary adenoma that secretes prolactin and TSH.
Management Trans-sphenoidal resection of the pituitary tumor. After surgery, T3 suppression test failed to completely suppress TSH secretion, which suggested a persistence of residual adenomatous cells. Hyperthyroidism and hypogonadism recurred after 5 years, therefore, treatment with lanreotide was initiated, and resulted in complete resolution of signs and symptoms of the disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Beck-Peccoz P et al. (1996) Thyrotropin-secreting pituitary tumors. Endocr Rev 17: 610–638
Yamakita N et al. (1995) Thyrotropin-producing pituitary adenoma discovered as a pituitary incidentaloma. Intern Med 34: 1055–1060
Losa M et al. (1996) Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 81: 3084–3090
Brucker-Davis F et al. (1999) Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 84: 476–486
Socin HV et al. (2003) The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 148: 433–442
Mannavola D et al. (2005) Different response to chronic somatostatin analogues in patients with central hyperthyroidism. Clin Endocrinol 62: 176–181
Beck-Peccoz P and Persani L (1994) Variable biological activity of thyroid-stimulating hormone. Eur J Endocrinol 131: 331–340
Persani L et al. (1998) Changes in the degree of sialylation of carbohydrate chains modify the biological properties of circulating thyrotropin isoforms in various physiological and pathological states. J Clin Endocrinol Metab 83: 2486–2492
Beck-Peccoz P et al. (1990) Sex hormone-binding globulin measurement in patients with inappropriate secretion of thyrotropin (IST): evidence against selective pituitary thyroid hormone resistance in nonneoplastic IST. J Clin Endocrinol Metab 71: 19–25
Persani L et al. (1997) Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH. Clin Endocrinol (Oxf) 47: 207–214
Pasquini E et al. (2003) Ectopic TSH-secreting pituitary adenoma of the vomerosphenoidal junction. Eur J Endocrinol 148: 253–257
Watanabe K et al. (1993) Thyrotropin-producing adenoma associated with pituitary resistance to thyroid hormone. J Clin Endocrinol Metab 76: 1025–1030
Ando S et al. (2001) Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab 86: 5572–5576
Chanson P et al. (1993) Octreotide therapy for thyroid stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 119: 236–240
Kuhn JM et al. (2000) Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 85: 1487–1491
Acknowledgements
These investigations were supported in part by Fondazione Ospedale Maggiore IRCCS, Milan, Italy.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Beck-Peccoz, P., Persani, L. TSH-induced hyperthyroidism caused by a pituitary tumor. Nat Rev Endocrinol 2, 524–528 (2006). https://doi.org/10.1038/ncpendmet0276
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0276
This article is cited by
-
Pathologic and clinical features of pituitary adenomas showing TSH immunoreactivity
Pituitary (2013)
-
Excess mortality for patients with residual disease following resection of pituitary adenomas
Pituitary (2011)
-
TSH-secreting adenomas: Rare pituitary tumors with multifaceted clinical and biological features
Journal of Endocrinological Investigation (2007)